Our Experts

Rachna T. Shroff, MD, MS

Rachna T. Shroff, MD, MS
  • Interim Chief of Hematology and Oncology
  • Associate Professor of Medicine, Tenure-Track
  • Chief, Section of GI Medical Oncology
  • Leader, University of Arizona Cancer Center GI Clinical Research Team
  • Associate Director, Clinical Investigations for University of Arizona Cancer Center
  • Associate Dean, Clinical and Translational Research – UA College of Medicine-Tucson
  • Associate Professor, Cancer Biology-GIDP
  • Medical Director, Arizona Clinical Trials Network (ACTN)
    Department of Medicine
  • Division of Hematology/Oncology, University of Arizona Cancer Center

Rachna T. Shroff, MD, MS, is an Associate Professor of Medicine and Chief of GI Medical Oncology as well as Leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC). She is the Director of UACC’s Clinical Trials Office as well as the Director of the Arizona Clinical Trials Network (ACTN), as well as Associate Dean for Clinical and Translational Research for UA College of Medicine-Tucson. More recently, most recently appointed Interim Chief of Division of Hematology and Oncology. She came to UACC from MD Anderson Cancer Center in Houston, TX where she was on faculty from 2010-2018 after completing her medical oncology fellowship there.

Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and hepatobiliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary subcommittee Co-Chair for the Southwest Oncology Group (SWOG) and as a Leadership Committee member for GI ASCO. Most recently, she was elected to serve on the ASCO Nominating Committee. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology.

Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.


University of Arizona Cancer Center

  • Leading expert in pancreatic and biliary cancer
  • Medical Director of the Clinical Trials Office and the Clinical Trials Network
  • Chief of the GI Medical Oncology section
  • Associate Dean of Clinical and Translational Research for the College of Medicine
  • Recipient of multiple mentorship and research awards